Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer

被引：0
作者：
Kim, Jin-Soo [1 ]
Han, Hye-Suk [1 ]
Im, Seock-Ah [1 ]
Oh, Do-Youn [1 ]
Han, Won-Shik [1 ]
Lee, Se-Hoon [1 ]
Kim, Dong-Wan [1 ]
Kim, Tae-You [1 ]
Noh, Dong-Young [1 ]
Bang, Yung-Jue [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [41] High pathologic complete response after primary chemotherapy in patients treated with weekly paclitaxel followed by FEC chemotherapy with simultaneous trastuzumab in Her-2 positive operable breast cancer
    Pernas, S.
    Gil Gil, M.
    Urruticoechea, A.
    Fernandez-Ortega, A.
    Falo, C.
    Piulats, J. M.
    Prieto, L.
    Pla, M. J.
    Moreno, A.
    Germa, J. R.
    ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
  • [42] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [43] A phase I study of interferon-gamma (γ) plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, H. S.
    Khong, H.
    Costa, R.
    Loftus, L.
    Goodridge, D.
    Henry, T.
    Soliman, H.
    Ismail-Khan, R.
    Fridley, B.
    Czerniecki, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+metastatic breast cancer
    Esteva, F. J.
    Franco, S.
    Hagan, M. K.
    Brewster, A.
    Williams, W.
    Florance, A. M.
    Koch, K.
    Turner, S. J.
    Ridderheim, M.
    Perez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
    Aitelhaj, Meryem
    Lkhoyaali, Siham
    Rais, Ghizlane
    Boutayeb, Saber
    Errihani, Hassan
    PAN AFRICAN MEDICAL JOURNAL, 2016, 24
  • [46] Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
    Moser, Sarah Sharman
    Apter, Lior
    Livnat, Idit
    Ginsburg, Roni
    Yarden, Adva
    Drori, Michal
    Drizon, Anat
    Chodick, Gabriel
    Siegelmann-Danieli, Nava
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 105 - 116
  • [47] Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase II study
    Fountzilas, G
    Tsavdaridis, D
    Kalogera-Fountzila, A
    Christodoulou, C
    Timotheadou, E
    Kalofonos, C
    Kosmidis, P
    Adamou, A
    Papakostas, P
    Gogas, H
    Stathopoulos, G
    Razis, E
    Bafaloukos, D
    Skarlos, D
    ANNALS OF ONCOLOGY, 2001, 12 (11) : 1545 - 1551
  • [48] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [49] Cardiac safety of trastuzumab in combination with epirubicin/cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer
    Untch, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Jaenicke, F.
    Muscholl, M.
    Pauschinger, M.
    Lehle, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [50] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Pier Paolo M. Berton Giachetti
    Giuseppe Curigliano
    Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
12345